Get the Stockscreener App
7.48
0.07%
-0.005
After Hours:
7.45
-0.03
-0.40%
Mind Medicine Inc stock is traded at $7.48, with a volume of 868.84K.
It is down -0.07% in the last 24 hours and up +23.43% over the past month.
See More
Previous Close:
$7.485
Open:
$7.62
24h Volume:
868.84K
Relative Volume:
0.80
Market Cap:
$548.52M
Revenue:
$11.40B
Net Income/Loss:
$-95.73M
P/E Ratio:
-3.7588
EPS:
-1.99
Net Cash Flow:
$-64.37M
1W Performance:
-9.44%
1M Performance:
+23.43%
6M Performance:
-9.33%
1Y Performance:
+107.20%
1-Day Range:
$7.31
$7.6905
1-Week Range:
$7.26
$8.555
52-Week Range:
$2.92
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Name
Mind Medicine Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare MNMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
7.48 | 548.52M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.98 | 119.49B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.26 | 82.89B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
624.96 | 37.37B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
254.72 | 32.85B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.70 | 27.50B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Mind Medicine Inc Stock (MNMD) Latest News
MindMed appoints new VP of R&D Strategy By Investing.com - Investing.com UK
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy - Milton Daily Standard
MindMed Announces New Employee Inducement Grants - Business Wire
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3%Time to Sell? - MarketBeat
Ally Bridge Group NY LLC Decreases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine (NEOE:MMED) Change In Inventory : C$0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com
Roth Capital Issues Pessimistic Estimate for MNMD Earnings - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.38 Average Price Target from Brokerages - MarketBeat
Generalized Anxiety Disorder Market to Reach New Heights - openPR
MindMed recruits regulatory expert ahead of Phase III trials - The Pharma Letter
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer - BioSpace
MindMed Appoints Former Karuna Executive to Lead Phase 3 Regulatory Strategy | MNMD Stock News - StockTitan
(MNMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
Stock Traders Purchase Large Volume of Call Options on Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
COMMODORE CAPITAL LP Acquires Shares in Mind Medicine Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions - Yahoo Finance
Mind Medicine Mindmed Inc (MNMD-Q) QuotePress Release - The Globe and Mail
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed)'s (MNMD) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Adam Stanecki on Mind Medicine with Charles Kovess11 November 2023 - imdb
MindMed Advances Phase 3 Trials in Mental Health - TipRanks
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... By GuruFocus - Investing.com Canada
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Stron - GuruFocus.com
Mind Medicine Inc (MNMD) Q3 2024 Earnings Call Highlights: Strong Cash Position and Clinical ... - Yahoo Finance
Certain Common Stock of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
Certain Restricted Stock Units of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
Certain Warrants of Mind Medicine Inc. are subject to a Lock-Up Agreement Ending on 8-NOV-2024. - Marketscreener.com
MindMed Reports Third Quarter 2024 Financial Results and Business Updates - Business Wire
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Up 10.1%What's Next? - MarketBeat
Mind Medicine’s Financial Health and Phase 3 Progress - TipRanks
(MNMD) Trading Report - Stock Traders Daily
Mind Medicine: Two Pathways Created From One Pipeline Clinical Candidate (NASDAQ:MNMD) - Seeking Alpha
Mind Medicine (MindMed) (MNMD) to Release Quarterly Earnings on Thursday - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
MNMDMind Medicine (MindMed) Inc. Common Shares Latest Stock News & Market Updates - StockTitan
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update - The Globe and Mail
FDA is said to see “path forward” for ecstasy-based drug (DRUG:NASDAQ) - Seeking Alpha
MindMed announces exchange agreement with investors By Investing.com - Investing.com
Bright Minds rally ends as psychedelic stocks extend volatility - MSN
Bright Minds stock cools amid psychedelic volatility (DRUG:NASDAQ) - Seeking Alpha
(MNMD) Investment Analysis and Advice - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Coverage Initiated at Leerink Partners - MarketBeat
Mind Medicine Inc Stock (MNMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
3.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):